25 XP   0   0   10

ACADIA Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyse Acadia together

PenkeI guess you are interested in ACADIA Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of ACADIA Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about ACADIA Pharmaceuticals Inc

I send you an email if I find something interesting about ACADIA Pharmaceuticals Inc.

Quick analysis of Acadia (30 sec.)










What can you expect buying and holding a share of Acadia? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$2.59
Expected worth in 1 year
$2.76
How sure are you?
25.0%

+ What do you gain per year?

Total Gains per Share
$0.16
Return On Investment
1.0%

For what price can you sell your share?

Current Price per Share
$17.07
Expected price per share
$16.13 - $18.63
How sure are you?
50%

1. Valuation of Acadia (5 min.)




Live pricePrice per Share (EOD)

$17.07

Intrinsic Value Per Share

$1.84 - $34.19

Total Value Per Share

$4.43 - $36.79

2. Growth of Acadia (5 min.)




Is Acadia growing?

Current yearPrevious yearGrowGrow %
How rich?$431.7m$426.4m-$35.4m-9.1%

How much money is Acadia making?

Current yearPrevious yearGrowGrow %
Making money-$15.3m-$53.9m$38.6m252.4%
Net Profit Margin-11.7%-43.6%--

How much money comes from the company's main activities?

3. Financial Health of Acadia (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#133 / 1016

Most Revenue
#78 / 1016

Most Profit
#634 / 1016

Most Efficient
#481 / 1016

What can you expect buying and holding a share of Acadia? (5 min.)

Welcome investor! Acadia's management wants to use your money to grow the business. In return you get a share of Acadia.

What can you expect buying and holding a share of Acadia?

First you should know what it really means to hold a share of Acadia. And how you can make/lose money.

Speculation

The Price per Share of Acadia is $17.07. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Acadia.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Acadia, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $2.59. Based on the TTM, the Book Value Change Per Share is $0.04 per quarter. Based on the YOY, the Book Value Change Per Share is $-0.21 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Acadia.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps0.281.6%-0.19-1.1%-0.33-1.9%-0.31-1.8%-0.32-1.9%
Usd Book Value Change Per Share0.392.3%0.040.2%-0.21-1.2%-0.02-0.1%0.040.2%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share0.392.3%0.040.2%-0.21-1.2%-0.02-0.1%0.040.2%
Usd Price Per Share31.31-23.73-17.65-28.67-28.65-
Price to Earnings Ratio28.46--4.47--16.60--20.73--23.67-
Price-to-Total Gains Ratio79.28-11.39--168.22--12.16--67.41-
Price to Book Ratio12.07-9.96-6.80-9.07-11.76-
Price-to-Total Gains Ratio79.28-11.39--168.22--12.16--67.41-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share17.07
Number of shares58
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.04-0.02
Usd Total Gains Per Share0.04-0.02
Gains per Quarter (58 shares)2.36-0.91
Gains per Year (58 shares)9.45-3.65
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
109-10-4-14
201980-7-18
3028170-11-22
4038260-15-26
5047350-18-30
6057440-22-34
7066530-26-38
8076620-29-42
9085710-33-46
10094800-36-50

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%1.019.00.05.0%1.039.00.02.5%2.079.01.02.4%
Book Value Change Per Share2.02.00.050.0%3.09.00.025.0%6.014.00.030.0%10.030.00.025.0%23.059.00.028.0%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.082.00.0%
Total Gains per Share2.02.00.050.0%3.09.00.025.0%6.014.00.030.0%10.030.00.025.0%23.059.00.028.0%

Fundamentals of Acadia

About ACADIA Pharmaceuticals Inc

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Fundamental data was last updated by Penke on 2024-04-10 23:22:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of ACADIA Pharmaceuticals Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Acadia earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • A Net Profit Margin of 19.8% means that $0.20 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 19.8%. The company is making a huge profit. +2
  • The TTM is -11.7%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ19.8%TTM-11.7%+31.5%
TTM-11.7%YOY-43.6%+32.0%
TTM-11.7%5Y-46.3%+34.7%
5Y-46.3%10Y-175,003.4%+174,957.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ19.8%-197.2%+217.0%
TTM-11.7%-210.4%+198.7%
YOY-43.6%-279.3%+235.7%
5Y-46.3%-436.8%+390.5%
10Y-175,003.4%-599.3%-174,404.1%
1.1.2. Return on Assets

Shows how efficient Acadia is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • 6.1% Return on Assets means that Acadia generated $0.06 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 6.1%. Using its assets, the company is efficient in making profit. +1
  • The TTM is -2.6%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ6.1%TTM-2.6%+8.8%
TTM-2.6%YOY-8.8%+6.2%
TTM-2.6%5Y-7.3%+4.7%
5Y-7.3%10Y-10.7%+3.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.1%-13.6%+19.7%
TTM-2.6%-12.9%+10.3%
YOY-8.8%-11.9%+3.1%
5Y-7.3%-14.2%+6.9%
10Y-10.7%-16.2%+5.5%
1.1.3. Return on Equity

Shows how efficient Acadia is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • 10.6% Return on Equity means Acadia generated $0.11 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 10.6%. Using its investors money, the company is less efficient in making profit.
  • The TTM is -4.7%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ10.6%TTM-4.7%+15.3%
TTM-4.7%YOY-12.5%+7.9%
TTM-4.7%5Y-9.5%+4.9%
5Y-9.5%10Y-12.5%+3.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ10.6%-17.0%+27.6%
TTM-4.7%-16.1%+11.4%
YOY-12.5%-15.4%+2.9%
5Y-9.5%-20.0%+10.5%
10Y-12.5%-21.1%+8.6%

1.2. Operating Efficiency of ACADIA Pharmaceuticals Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Acadia is operating .

  • Measures how much profit Acadia makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • An Operating Margin of 15.1% means the company generated $0.15  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 15.1%. The company is operating efficient. +1
  • The TTM is -14.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ15.1%TTM-14.5%+29.6%
TTM-14.5%YOY-45.3%+30.9%
TTM-14.5%5Y-48.7%+34.2%
5Y-48.7%10Y-175,889.6%+175,840.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ15.1%-286.1%+301.2%
TTM-14.5%-224.4%+209.9%
YOY-45.3%-288.4%+243.1%
5Y-48.7%-475.2%+426.5%
10Y-175,889.6%-624.7%-175,264.9%
1.2.2. Operating Ratio

Measures how efficient Acadia is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.85 means that the operating costs are $0.85 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 0.849. The company is less efficient in keeping operating costs low.
  • The TTM is 1.139. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ0.849TTM1.139-0.290
TTM1.139YOY1.451-0.312
TTM1.1395Y1.481-0.342
5Y1.48110Y3,183.838-3,182.358
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8492.997-2.148
TTM1.1393.247-2.108
YOY1.4513.766-2.315
5Y1.4815.675-4.194
10Y3,183.8387.857+3,175.981

1.3. Liquidity of ACADIA Pharmaceuticals Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Acadia is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 2.42 means the company has $2.42 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 2.423. The company is able to pay all its short-term debts. +1
  • The TTM is 2.417. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.423TTM2.417+0.006
TTM2.417YOY4.394-1.977
TTM2.4175Y5.935-3.518
5Y5.93510Y11.093-5.159
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.4233.930-1.507
TTM2.4174.251-1.834
YOY4.3945.436-1.042
5Y5.9356.045-0.110
10Y11.0936.363+4.730
1.3.2. Quick Ratio

Measures if Acadia is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • A Quick Ratio of 3.11 means the company can pay off $3.11 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 3.113. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 3.218. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ3.113TTM3.218-0.105
TTM3.218YOY6.489-3.271
TTM3.2185Y8.722-5.504
5Y8.72210Y18.273-9.551
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.1133.629-0.516
TTM3.2184.065-0.847
YOY6.4895.397+1.092
5Y8.7225.993+2.729
10Y18.2736.277+11.996

1.4. Solvency of ACADIA Pharmaceuticals Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Acadia assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Acadia to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.42 means that Acadia assets are financed with 42.4% credit (debt) and the remaining percentage (100% - 42.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 0.424. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.416. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.424TTM0.416+0.008
TTM0.416YOY0.298+0.118
TTM0.4165Y0.246+0.170
5Y0.24610Y0.164+0.082
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.4240.332+0.092
TTM0.4160.334+0.082
YOY0.2980.268+0.030
5Y0.2460.366-0.120
10Y0.1640.390-0.226
1.4.2. Debt to Equity Ratio

Measures if Acadia is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Acadia to the Biotechnology industry mean.
  • A Debt to Equity ratio of 73.5% means that company has $0.73 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of ACADIA Pharmaceuticals Inc:

  • The MRQ is 0.735. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.714. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.735TTM0.714+0.021
TTM0.714YOY0.424+0.290
TTM0.7145Y0.354+0.360
5Y0.35410Y0.223+0.131
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.7350.381+0.354
TTM0.7140.390+0.324
YOY0.4240.334+0.090
5Y0.3540.434-0.080
10Y0.2230.466-0.243

2. Market Valuation of ACADIA Pharmaceuticals Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Acadia generates.

  • Above 15 is considered overpriced but always compare Acadia to the Biotechnology industry mean.
  • A PE ratio of 28.46 means the investor is paying $28.46 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of ACADIA Pharmaceuticals Inc:

  • The EOD is 15.516. Based on the earnings, the company is fair priced.
  • The MRQ is 28.459. Based on the earnings, the company is overpriced. -1
  • The TTM is -4.474. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD15.516MRQ28.459-12.944
MRQ28.459TTM-4.474+32.933
TTM-4.474YOY-16.600+12.126
TTM-4.4745Y-20.729+16.256
5Y-20.72910Y-23.667+2.937
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD15.516-2.315+17.831
MRQ28.459-2.560+31.019
TTM-4.474-2.664-1.810
YOY-16.600-4.122-12.478
5Y-20.729-6.258-14.471
10Y-23.667-6.108-17.559
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of ACADIA Pharmaceuticals Inc:

  • The EOD is 8.322. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 15.264. Based on how much money comes from the company's main activities, the company is underpriced. +1
  • The TTM is -18.398. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD8.322MRQ15.264-6.942
MRQ15.264TTM-18.398+33.662
TTM-18.398YOY-252.942+234.544
TTM-18.3985Y-81.795+63.397
5Y-81.79510Y-58.933-22.862
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD8.322-3.067+11.389
MRQ15.264-3.251+18.515
TTM-18.398-3.545-14.853
YOY-252.942-5.595-247.347
5Y-81.795-8.315-73.480
10Y-58.933-8.708-50.225
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Acadia is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 12.07 means the investor is paying $12.07 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of ACADIA Pharmaceuticals Inc:

  • The EOD is 6.583. Based on the equity, the company is overpriced. -1
  • The MRQ is 12.075. Based on the equity, the company is expensive. -2
  • The TTM is 9.957. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.583MRQ12.075-5.492
MRQ12.075TTM9.957+2.118
TTM9.957YOY6.799+3.159
TTM9.9575Y9.067+0.890
5Y9.06710Y11.757-2.690
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.5831.905+4.678
MRQ12.0752.111+9.964
TTM9.9572.095+7.862
YOY6.7992.836+3.963
5Y9.0673.443+5.624
10Y11.7573.794+7.963
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of ACADIA Pharmaceuticals Inc.

3.1. Institutions holding ACADIA Pharmaceuticals Inc

Institutions are holding 99.566% of the shares of ACADIA Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2023-12-31Baker Bros Advisors LP26.014615.27084286461200
2023-12-31Vanguard Group Inc8.13010.009213396009-220731-1.621
2023-12-31BlackRock Inc6.9250.009111410483138189813.7796
2023-12-31RTW INVESTMENTS, LLC6.82985.503811253551-322986-2.79
2023-12-31State Street Corporation3.92360.00996465026125129524
2023-12-31EcoR1 Capital, LLC3.63624.8706599147900
2023-12-31FMR Inc3.19560.01275265358-36622-0.6907
2023-12-31T. Rowe Price Associates, Inc.3.14280.02185178509-51652-0.9876
2023-09-30D. E. Shaw & Co LP2.90640.10424788998-474080-9.0077
2023-12-31Fred Alger Management, LLC1.9280.53663176775678922.1838
2023-12-31Geode Capital Management, LLC1.63390.008826921521137704.4125
2023-12-31Palo Alto Investors, LLC1.46246.7973240955637630.1564
2023-12-31First Trust Advisors L.P.1.07860.060717773071485269.1188
2023-12-31Millennium Management LLC1.0710.02391764678-648786-26.8819
2023-12-31Emerald Advisers, LLC0.99872.20521645565-35487-2.111
2023-12-31Goldman Sachs Group Inc0.97610.00451608340889715123.808
2023-12-31Pictet Asset Manangement SA0.88680.050514612321096358.1115
2023-12-31NORGES BANK0.87590.00791443218-510938-26.1462
2023-09-30Jacobs Levy Equity Management, Inc.0.86450.17581424403-411615-22.4189
2023-12-31Morgan Stanley - Brokerage Accounts0.82650.00381361900-494480-26.6368
Total 77.306535.6871127379151+759117+0.6%

3.2. Funds holding ACADIA Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-02-29SPDR® S&P Biotech ETF2.4411.18044022072751231.9033
2024-02-29Vanguard Total Stock Mkt Idx Inv2.33280.00583843782-11773-0.3054
2024-02-29Vanguard Small Cap Index1.92630.05253173959295230.9389
2024-02-29iShares Russell 2000 ETF1.78380.10952939211-480-0.0163
2024-01-31Fidelity Growth Compy Commingled Pl O1.45240.08652393153-101784-4.0796
2024-02-29Vanguard Small Cap Growth Index Inv1.07860.11841777231225861.2872
2024-02-29Vanguard Institutional Extnd Mkt Idx Tr1.07160.0402176566813150.0745
2023-12-31US Small-Cap Growth II Equity Comp1.03480.2151705113-5450-0.3186
2023-12-31T. Rowe Price New Horizons1.03480.21581705113-5450-0.3186
2024-01-31Fidelity Growth Company Fund0.98720.07691626556-65115-3.8492
2024-02-29First Trust NYSE Arca Biotech ETF0.83792.7207138067600
2024-02-29iShares Biotechnology ETF0.75680.3811247055-5610-0.4478
2023-12-31Fidelity Small Cap Index0.73190.14861205958152041.2768
2023-12-31T. Rowe Price Health Sciences0.72550.25441195370-68807-5.4428
2024-02-29iShares Russell 2000 Growth ETF0.64670.2181106558035180.3312
2023-12-31T. Rowe Price Integrated US Sm Gr Eq0.59560.394398131200
2023-12-31Alger Weatherbie Specialized Growth A0.57665.168950154-19619-2.0231
2023-12-31Eventide Healthcare & Life Sciences I0.49121.52048093918093910
2024-02-29State St Russell Sm/Mid Cp® Indx NL Cl C0.44480.0408732955194002.7188
2024-01-31Emerald Growth A0.41621.962468581100
Total 21.366514.909735206120+691972+2.0%

3.3. Insider Transactions

Insiders are holding 0.474% of the shares of ACADIA Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-04-08James KiharaSELL179017.87
2024-04-08Mark C SchneyerSELL271617.87
2024-04-08Stephen DavisSELL2657417.87
2024-04-08Brendan TeehanSELL256817.87
2024-03-27Brendan TeehanSELL514017.9
2024-03-27Mark C SchneyerSELL543417.9
2024-03-27Stephen DavisSELL1771417.9
2024-02-26Brendan TeehanSELL62424.67
2024-02-26James KiharaSELL47424.67
2024-02-26Mark C SchneyerSELL77224.67
2024-02-26Stephen DavisSELL557724.67
2024-01-08Austin D KimSELL59029.96
2024-01-08Brendan TeehanSELL73129.96
2024-01-08Stephen DavisSELL373229.96
2023-12-15James KiharaSELL200028.3
2023-11-20Mark C SchneyerSELL510822.64
2023-11-20Brendan TeehanSELL496022.64
2023-11-20James KiharaSELL198522.64
2023-10-06Austin D KimSELL1636921.96
2023-10-06Stephen DavisSELL5156321.96

4. Summary

4.1. Key Performance Indicators

The key performance indicators of ACADIA Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.3950.041+870%-0.213+154%-0.016+104%0.037+962%
Book Value Per Share--2.5932.365+10%2.588+0%3.125-17%2.644-2%
Current Ratio--2.4232.417+0%4.394-45%5.935-59%11.093-78%
Debt To Asset Ratio--0.4240.416+2%0.298+42%0.246+72%0.164+158%
Debt To Equity Ratio--0.7350.714+3%0.424+73%0.354+107%0.223+229%
Dividend Per Share----0%-0%-0%-0%
Eps--0.275-0.194+171%-0.328+219%-0.312+213%-0.317+215%
Free Cash Flow Per Share--0.513-0.037+107%-0.173+134%-0.170+133%-0.206+140%
Free Cash Flow To Equity Per Share--0.5450.001+40906%-0.161+129%-0.017+103%0.036+1433%
Gross Profit Margin--1.0001.0000%1.033-3%1.017-2%1.009-1%
Intrinsic Value_10Y_max--34.194--------
Intrinsic Value_10Y_min--1.837--------
Intrinsic Value_1Y_max--0.038--------
Intrinsic Value_1Y_min---0.658--------
Intrinsic Value_3Y_max--2.696--------
Intrinsic Value_3Y_min---1.259--------
Intrinsic Value_5Y_max--8.467--------
Intrinsic Value_5Y_min---1.070--------
Market Cap2812658040.000-85%5213428100.0003925284330.000+33%2907813870.000+79%4727309352.000+10%4721583189.000+10%
Net Profit Margin--0.198-0.117+159%-0.436+320%-0.463+334%-1750.034+882974%
Operating Margin--0.151-0.145+196%-0.453+400%-0.487+422%-1758.896+1163038%
Operating Ratio--0.8491.139-25%1.451-41%1.481-43%3183.838-100%
Pb Ratio6.583-83%12.0759.957+21%6.799+78%9.067+33%11.757+3%
Pe Ratio15.516-83%28.459-4.474+116%-16.600+158%-20.729+173%-23.667+183%
Price Per Share17.070-83%31.31023.730+32%17.648+77%28.672+9%28.646+9%
Price To Free Cash Flow Ratio8.322-83%15.264-18.398+221%-252.942+1757%-81.795+636%-58.933+486%
Price To Total Gains Ratio43.222-83%79.27911.389+596%-168.225+312%-12.156+115%-67.413+185%
Quick Ratio--3.1133.218-3%6.489-52%8.722-64%18.273-83%
Return On Assets--0.061-0.026+143%-0.088+244%-0.073+220%-0.107+275%
Return On Equity--0.106-0.047+144%-0.125+218%-0.095+190%-0.125+218%
Total Gains Per Share--0.3950.041+870%-0.213+154%-0.016+104%0.037+962%
Usd Book Value--431755000.000390995000.000+10%426436000.000+1%515149100.000-16%435844225.000-1%
Usd Book Value Change Per Share--0.3950.041+870%-0.213+154%-0.016+104%0.037+962%
Usd Book Value Per Share--2.5932.365+10%2.588+0%3.125-17%2.644-2%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps--0.275-0.194+171%-0.328+219%-0.312+213%-0.317+215%
Usd Free Cash Flow--85389000.000-5837000.000+107%-28508750.000+133%-28008850.000+133%-33973200.000+140%
Usd Free Cash Flow Per Share--0.513-0.037+107%-0.173+134%-0.170+133%-0.206+140%
Usd Free Cash Flow To Equity Per Share--0.5450.001+40906%-0.161+129%-0.017+103%0.036+1433%
Usd Market Cap2812658040.000-85%5213428100.0003925284330.000+33%2907813870.000+79%4727309352.000+10%4721583189.000+10%
Usd Price Per Share17.070-83%31.31023.730+32%17.648+77%28.672+9%28.646+9%
Usd Profit--45797000.000-15321500.000+133%-53993750.000+218%-48098700.000+205%-50622000.000+211%
Usd Revenue--231041000.000181609250.000+27%129308750.000+79%125432400.000+84%71871700.000+221%
Usd Total Gains Per Share--0.3950.041+870%-0.213+154%-0.016+104%0.037+962%
 EOD+4 -4MRQTTM+26 -7YOY+25 -95Y+22 -1210Y+22 -12

4.2. Fundamental Score

Let's check the fundamental score of ACADIA Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1515.516
Price to Book Ratio (EOD)Between0-16.583
Net Profit Margin (MRQ)Greater than00.198
Operating Margin (MRQ)Greater than00.151
Quick Ratio (MRQ)Greater than13.113
Current Ratio (MRQ)Greater than12.423
Debt to Asset Ratio (MRQ)Less than10.424
Debt to Equity Ratio (MRQ)Less than10.735
Return on Equity (MRQ)Greater than0.150.106
Return on Assets (MRQ)Greater than0.050.061
Total7/10 (70.0%)

4.3. Technical Score

Let's check the technical score of ACADIA Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.910
Ma 20Greater thanMa 5017.800
Ma 50Greater thanMa 10021.174
Ma 100Greater thanMa 20024.037
OpenGreater thanClose17.260
Total1/5 (20.0%)



Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2022-12-312023-03-312023-06-302023-09-302023-12-31
Accumulated Other Comprehensive Income  -975755-220-315-535216-31934324



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets748,956
Total Liabilities317,201
Total Stockholder Equity431,755
 As reported
Total Liabilities 317,201
Total Stockholder Equity+ 431,755
Total Assets = 748,956

Assets

Total Assets748,956
Total Current Assets616,125
Long-term Assets132,831
Total Current Assets
Cash And Cash Equivalents 188,657
Short-term Investments 250,208
Net Receivables 102,350
Inventory 35,819
Other Current Assets 39,091
Total Current Assets  (as reported)616,125
Total Current Assets  (calculated)616,125
+/-0
Long-term Assets
Property Plant Equipment 56,467
Long-term Assets Other 5,104
Long-term Assets  (as reported)132,831
Long-term Assets  (calculated)61,571
+/- 71,260

Liabilities & Shareholders' Equity

Total Current Liabilities254,254
Long-term Liabilities62,947
Total Stockholder Equity431,755
Total Current Liabilities
Short-term Debt 9,405
Accounts payable 17,543
Other Current Liabilities 225,742
Total Current Liabilities  (as reported)254,254
Total Current Liabilities  (calculated)252,690
+/- 1,564
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt47,800
Long-term Liabilities Other 15,147
Long-term Liabilities  (as reported)62,947
Long-term Liabilities  (calculated)62,947
+/-0
Total Stockholder Equity
Common Stock16
Retained Earnings -2,430,837
Accumulated Other Comprehensive Income 24
Other Stockholders Equity 2,862,552
Total Stockholder Equity (as reported)431,755
Total Stockholder Equity (calculated)431,755
+/-0
Other
Capital Stock16
Cash and Short Term Investments 438,865
Common Stock Shares Outstanding 166,510
Current Deferred Revenue1,564
Liabilities and Stockholders Equity 748,956
Net Debt -131,452
Net Invested Capital 431,755
Net Working Capital 361,871
Property Plant and Equipment Gross 66,023
Short Long Term Debt Total 57,205



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312000-09-30
> Total Assets 
33,471
16,023
0
0
0
31,693
27,416
53,304
47,750
40,365
45,924
73,631
70,271
62,506
63,518
115,568
100,914
89,544
75,748
160,221
148,346
134,584
113,325
96,080
78,203
64,677
50,371
70,063
58,475
49,680
43,273
39,166
35,750
38,394
46,887
41,309
37,022
32,114
26,519
21,874
23,750
108,590
103,015
206,909
199,285
189,118
373,506
359,465
341,763
325,458
301,963
275,539
245,320
221,896
466,590
438,034
617,384
561,153
503,013
456,315
413,714
384,506
351,040
314,960
266,456
540,202
501,105
460,883
765,586
783,183
747,450
759,649
795,664
782,616
755,173
724,429
717,673
700,122
624,251
612,766
602,491
587,812
655,305
642,769
632,540
748,956
748,956632,540642,769655,305587,812602,491612,766624,251700,122717,673724,429755,173782,616795,664759,649747,450783,183765,586460,883501,105540,202266,456314,960351,040384,506413,714456,315503,013561,153617,384438,034466,590221,896245,320275,539301,963325,458341,763359,465373,506189,118199,285206,909103,015108,59023,75021,87426,51932,11437,02241,30946,88738,39435,75039,16643,27349,68058,47570,06350,37164,67778,20396,080113,325134,584148,346160,22175,74889,544100,914115,56863,51862,50670,27173,63145,92440,36547,75053,30427,41631,69300016,02333,471
   > Total Current Assets 
0
0
0
0
0
28,272
23,690
50,258
44,905
37,818
43,653
71,398
68,000
60,125
61,121
112,661
97,804
85,783
72,365
156,893
144,951
131,253
110,170
93,107
75,535
62,382
48,287
68,214
56,804
48,473
42,267
38,318
34,992
37,849
46,548
41,015
36,763
31,949
26,387
21,775
23,685
108,548
102,985
206,761
198,675
188,360
372,820
358,854
341,065
324,618
299,899
273,393
242,847
218,989
462,352
423,897
603,490
547,897
489,753
443,745
401,972
373,477
340,014
301,096
254,116
526,106
476,406
436,940
742,330
760,250
724,421
735,735
730,213
717,616
673,984
645,730
640,917
617,823
542,223
532,519
521,552
507,937
502,850
492,628
499,170
616,125
616,125499,170492,628502,850507,937521,552532,519542,223617,823640,917645,730673,984717,616730,213735,735724,421760,250742,330436,940476,406526,106254,116301,096340,014373,477401,972443,745489,753547,897603,490423,897462,352218,989242,847273,393299,899324,618341,065358,854372,820188,360198,675206,761102,985108,54823,68521,77526,38731,94936,76341,01546,54837,84934,99238,31842,26748,47356,80468,21448,28762,38275,53593,107110,170131,253144,951156,89372,36585,78397,804112,66161,12160,12568,00071,39843,65337,81844,90550,25823,69028,27200000
       Cash And Cash Equivalents 
0
4,454
0
0
0
6,308
4,368
8,157
5,693
8,302
11,236
15,812
23,353
9,796
11,264
38,420
26,229
15,480
22,315
39,631
23,462
16,987
21,005
20,285
22,213
21,171
18,840
17,984
17,322
18,122
18,067
8,811
9,656
6,849
6,829
8,020
8,317
6,889
5,558
9,208
8,016
57,899
18,436
24,247
11,803
11,707
96,455
13,698
36,369
61,854
76,424
93,212
70,799
102,138
175,220
131,774
153,679
163,620
157,383
143,789
112,616
69,418
116,328
74,182
63,897
134,758
97,557
74,432
385,474
189,680
173,059
310,441
452,352
326,028
304,487
266,956
94,640
147,435
204,920
139,833
154,842
114,846
290,895
107,941
98,193
188,657
188,65798,193107,941290,895114,846154,842139,833204,920147,43594,640266,956304,487326,028452,352310,441173,059189,680385,47474,43297,557134,75863,89774,182116,32869,418112,616143,789157,383163,620153,679131,774175,220102,13870,79993,21276,42461,85436,36913,69896,45511,70711,80324,24718,43657,8998,0169,2085,5586,8898,3178,0206,8296,8499,6568,81118,06718,12217,32217,98418,84021,17122,21320,28521,00516,98723,46239,63122,31515,48026,22938,42011,2649,79623,35315,81211,2368,3025,6938,1574,3686,3080004,4540
       Short-term Investments 
0
7,985
0
0
0
20,906
18,126
40,636
37,465
27,626
30,410
53,148
39,378
33,205
32,420
55,715
68,428
67,775
47,584
114,238
117,500
109,871
85,494
69,336
50,485
38,912
27,544
48,168
37,587
28,938
22,509
25,464
22,570
30,238
38,835
32,341
27,833
24,159
20,366
12,141
15,042
50,068
83,027
181,204
184,377
174,083
272,830
340,755
301,430
260,632
221,469
177,565
169,892
112,994
282,023
280,781
435,180
365,416
312,098
273,531
254,009
271,924
181,735
182,673
150,239
338,762
316,767
307,455
298,373
507,749
478,347
348,110
192,089
305,930
273,281
289,962
445,651
373,271
241,057
296,518
281,737
301,977
111,978
267,437
247,727
250,208
250,208247,727267,437111,978301,977281,737296,518241,057373,271445,651289,962273,281305,930192,089348,110478,347507,749298,373307,455316,767338,762150,239182,673181,735271,924254,009273,531312,098365,416435,180280,781282,023112,994169,892177,565221,469260,632301,430340,755272,830174,083184,377181,20483,02750,06815,04212,14120,36624,15927,83332,34138,83530,23822,57025,46422,50928,93837,58748,16827,54438,91250,48569,33685,494109,871117,500114,23847,58467,77568,42855,71532,42033,20539,37853,14830,41027,62637,46540,63618,12620,9060007,9850
       Net Receivables 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,930
1,934
0
0
0
0
0
0
0
0
0
0
0
0
0
1,642
1,320
1,139
964
746
1,508
206
1,638
783
1,633
5,224
7,140
9,519
12,378
15,254
18,430
23,348
26,682
20,682
27,789
33,770
32,722
32,269
37,874
44,571
46,128
47,784
50,282
57,390
51,820
61,668
65,344
63,482
68,889
56,136
63,080
70,250
84,156
94,532
102,350
102,35094,53284,15670,25063,08056,13668,88963,48265,34461,66851,82057,39050,28247,78446,12844,57137,87432,26932,72233,77027,78920,68226,68223,34818,43015,25412,3789,5197,1405,2241,6337831,6382061,5087469641,1391,3201,64200000000000001,9342,9300000000000000000000000000000000
       Inventory 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,867
4,301
4,175
3,881
6,003
5,536
5,248
5,583
4,737
4,347
4,070
4,570
3,824
4,846
6,341
6,318
6,210
7,979
9,682
10,311
10,786
14,336
7,881
7,009
6,327
5,844
6,636
6,095
9,199
20,768
35,819
35,81920,7689,1996,0956,6365,8446,3277,0097,88114,33610,78610,3119,6827,9796,2106,3186,3414,8463,8244,5704,0704,3474,7375,5835,2485,5366,0033,8814,1754,3012,8670000000000000000000000000000000000000000000000000000000
   > Long-term Assets 
0
0
0
0
0
3,421
3,726
3,045
2,844
2,547
2,272
2,232
2,271
2,381
2,397
2,907
3,110
3,761
3,383
3,328
3,395
3,331
3,155
2,973
2,668
2,295
2,084
1,849
1,671
1,207
1,006
848
758
545
339
294
259
165
132
99
65
42
30
148
610
758
686
611
698
840
2,064
2,146
2,473
2,907
4,238
14,137
13,894
13,256
13,260
12,570
11,742
11,029
11,026
13,864
12,340
14,096
24,699
23,943
23,256
22,933
23,029
23,914
65,451
65,000
81,189
78,699
76,756
82,299
82,028
80,247
80,939
79,875
152,455
150,141
133,370
132,831
132,831133,370150,141152,45579,87580,93980,24782,02882,29976,75678,69981,18965,00065,45123,91423,02922,93323,25623,94324,69914,09612,34013,86411,02611,02911,74212,57013,26013,25613,89414,1374,2382,9072,4732,1462,064840698611686758610148304265991321652592943395457588481,0061,2071,6711,8492,0842,2952,6682,9733,1553,3313,3953,3283,3833,7613,1102,9072,3972,3812,2712,2322,2722,5472,8443,0453,7263,42100000
       Property Plant Equipment 
2,880
2,419
0
0
0
3,117
2,801
2,761
2,549
2,547
2,272
2,232
2,249
2,283
2,299
2,811
3,014
3,505
3,287
3,141
3,095
3,048
2,919
2,712
2,420
2,103
1,846
1,657
1,498
1,062
870
698
622
426
244
208
181
151
121
92
63
42
30
92
490
579
543
500
520
553
1,786
1,813
2,068
2,203
2,623
2,897
3,159
3,081
3,471
3,296
2,991
2,662
2,709
2,760
3,372
3,309
14,655
14,245
13,208
12,704
13,702
14,567
56,659
56,444
72,868
70,568
68,613
66,315
65,717
64,433
63,134
61,594
59,746
57,575
55,642
56,467
56,46755,64257,57559,74661,59463,13464,43365,71766,31568,61370,56872,86856,44456,65914,56713,70212,70413,20814,24514,6553,3093,3722,7602,7092,6622,9913,2963,4713,0813,1592,8972,6232,2032,0681,8131,78655352050054357949092304263921211511812082444266226988701,0621,4981,6571,8462,1032,4202,7122,9193,0483,0953,1413,2873,5053,0142,8112,2992,2832,2492,2322,2722,5472,5492,7612,8013,1170002,4192,880
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,900
1,182
1,300
1,100
1,100
1,800
2,300
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000002,3001,8001,1001,1001,3001,1822,900000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
7,754
7,385
7,015
6,646
6,277
5,907
5,538
5,169
4,800
4,431
4,062
3,692
3,323
2,954
2,585
2,215
1,846
1,477
1,108
738
369
0
0
0
0
0
0
69,583
68,219
66,855
0
066,85568,21969,5830000003697381,1081,4771,8462,2152,5852,9543,3233,6924,0624,4314,8005,1695,5385,9076,2776,6467,0157,3857,7540000000000000000000000000000000000000000000000000000000
       Long-term Assets Other 
0
0
0
0
0
304
925
285
295
0
0
0
22
98
98
96
96
256
96
187
300
283
236
261
248
192
238
192
173
145
136
150
136
119
95
86
78
14
11
7
2
0
0
56
120
179
143
111
178
-97,917
278
333
405
704
1,615
3,486
3,350
3,160
3,143
2,997
2,844
2,829
3,148
6,304
4,537
6,725
6,352
6,375
7,094
7,644
7,112
7,501
7,315
7,448
7,583
7,762
8,143
15,984
16,311
10,044
12,035
5,311
23,126
24,347
10,873
5,104
5,10410,87324,34723,1265,31112,03510,04416,31115,9848,1437,7627,5837,4487,3157,5017,1127,6447,0946,3756,3526,7254,5376,3043,1482,8292,8442,9973,1433,1603,3503,4861,615704405333278-97,917178111143179120560027111478869511913615013614517319223819224826123628330018796256969698982200029528592530400000
> Total Liabilities 
7,600
9,611
0
0
0
84,364
85,832
10,512
10,390
9,685
13,554
12,481
21,074
23,135
23,659
27,022
22,513
22,385
18,953
15,951
18,612
20,650
14,658
14,876
11,961
11,685
11,985
43,650
39,508
37,566
36,175
36,010
35,924
8,706
8,779
8,488
8,878
8,752
8,934
9,166
6,086
23,606
23,353
25,434
18,531
6,987
8,046
9,357
11,274
15,969
16,869
19,718
17,974
22,134
21,339
29,219
39,326
42,742
45,489
41,175
36,388
49,221
46,871
50,240
43,016
61,123
82,749
71,969
76,297
84,048
109,068
96,636
140,797
155,607
173,567
159,591
150,718
159,228
179,454
177,918
176,805
187,399
281,047
246,976
270,366
317,201
317,201270,366246,976281,047187,399176,805177,918179,454159,228150,718159,591173,567155,607140,79796,636109,06884,04876,29771,96982,74961,12343,01650,24046,87149,22136,38841,17545,48942,74239,32629,21921,33922,13417,97419,71816,86915,96911,2749,3578,0466,98718,53125,43423,35323,6066,0869,1668,9348,7528,8788,4888,7798,70635,92436,01036,17537,56639,50843,65011,98511,68511,96114,87614,65820,65018,61215,95118,95322,38522,51327,02223,65923,13521,07412,48113,5549,68510,39010,51285,83284,3640009,6117,600
   > Total Current Liabilities 
2,968
6,153
0
0
0
8,226
10,441
9,565
9,364
8,641
11,693
11,078
19,689
21,701
21,743
25,306
20,767
20,534
17,272
14,326
17,155
19,287
13,472
13,889
11,202
11,051
11,436
20,936
15,248
14,707
13,550
12,984
13,168
5,959
6,139
5,947
6,409
6,165
6,433
6,760
6,086
5,948
5,695
7,776
7,870
6,979
8,033
9,339
11,253
15,834
16,651
19,378
17,735
21,902
21,122
29,022
39,149
42,585
45,265
40,913
36,143
49,030
46,089
49,214
41,807
59,565
74,983
63,814
67,744
74,826
99,741
86,422
91,856
105,967
109,373
95,328
88,218
96,068
119,603
117,681
116,570
125,630
224,301
187,942
209,603
254,254
254,254209,603187,942224,301125,630116,570117,681119,60396,06888,21895,328109,373105,96791,85686,42299,74174,82667,74463,81474,98359,56541,80749,21446,08949,03036,14340,91345,26542,58539,14929,02221,12221,90217,73519,37816,65115,83411,2539,3398,0336,9797,8707,7765,6955,9486,0866,7606,4336,1656,4095,9476,1395,95913,16812,98413,55014,70715,24820,93611,43611,05111,20213,88913,47219,28717,15514,32617,27220,53420,76725,30621,74321,70119,68911,07811,6938,6419,3649,56510,4418,2260006,1532,968
       Short-term Debt 
0
0
0
0
0
3,242
3,167
2,604
2,059
1,486
845
855
926
890
805
826
902
996
1,039
1,047
1,017
978
934
882
815
795
685
560
450
365
291
161
111
78
44
40
37
32
22
13
3
0
0
0
0
0
0
0
0
2,822
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,468
4,412
3,889
3,434
2,909
2,653
3,857
5,087
6,082
7,521
8,150
8,304
8,944
9,024
9,231
9,305
9,173
9,058
9,031
9,405
9,4059,0319,0589,1739,3059,2319,0248,9448,3048,1507,5216,0825,0873,8572,6532,9093,4343,8894,4124,46800000000000000002,822000000003132232374044781111612913654505606857958158829349781,0171,0471,0399969028268058909268558451,4862,0592,6043,1673,24200000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,468
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000004,468000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
379
1,121
0
0
0
1,533
2,530
1,985
2,450
2,153
1,357
2,317
1,730
2,073
733
3,419
3,206
3,387
3,058
2,273
2,950
2,590
2,047
3,217
2,450
2,283
4,185
3,981
2,554
2,947
2,122
2,300
2,617
1,972
1,380
1,139
1,262
1,960
1,035
757
1,131
1,375
1,396
1,177
1,120
372
1,562
1,104
1,110
2,016
2,518
2,916
2,204
1,672
1,307
1,024
2,828
3,912
2,166
3,588
2,962
8,786
2,996
3,333
2,955
3,167
3,275
4,650
3,444
7,222
6,623
6,466
3,471
8,493
8,849
9,065
7,722
6,876
10,768
11,854
10,008
12,746
17,422
18,811
12,310
17,543
17,54312,31018,81117,42212,74610,00811,85410,7686,8767,7229,0658,8498,4933,4716,4666,6237,2223,4444,6503,2753,1672,9553,3332,9968,7862,9623,5882,1663,9122,8281,0241,3071,6722,2042,9162,5182,0161,1101,1041,5623721,1201,1771,3961,3751,1317571,0351,9601,2621,1391,3801,9722,6172,3002,1222,9472,5543,9814,1852,2832,4503,2172,0472,5902,9502,2733,0583,3873,2063,4197332,0731,7302,3171,3572,1532,4501,9852,5301,5330001,121379
       Other Current Liabilities 
1,260
2,057
0
0
0
2,131
2,423
2,990
3,201
3,681
3,657
3,405
12,865
15,292
16,164
17,145
13,868
13,485
10,050
8,510
11,524
15,012
10,321
9,620
7,767
7,535
6,474
7,270
6,340
5,358
5,048
4,128
3,760
3,219
4,253
4,015
4,402
3,504
4,693
5,225
4,686
4,139
4,159
6,488
6,670
6,552
6,429
8,206
10,128
13,818
14,133
16,462
15,531
20,230
19,815
27,485
34,445
36,029
38,967
37,325
33,181
40,244
43,093
45,881
38,852
56,398
67,240
54,752
60,411
64,170
90,209
77,303
84,528
92,387
94,442
78,742
72,346
80,888
99,891
96,803
97,331
103,579
197,706
169,131
197,293
225,742
225,742197,293169,131197,706103,57997,33196,80399,89180,88872,34678,74294,44292,38784,52877,30390,20964,17060,41154,75267,24056,39838,85245,88143,09340,24433,18137,32538,96736,02934,44527,48519,81520,23015,53116,46214,13313,81810,1288,2066,4296,5526,6706,4884,1594,1394,6865,2254,6933,5044,4024,0154,2533,2193,7604,1285,0485,3586,3407,2706,4747,5357,7679,62010,32115,01211,5248,51010,05013,48513,86817,14516,16415,29212,8653,4053,6573,6813,2012,9902,4232,1310002,0571,260
   > Long-term Liabilities 
0
0
0
0
0
76,138
75,391
946
1,026
1,044
1,861
1,403
1,385
1,433
1,916
1,716
1,746
1,851
1,681
1,625
1,457
1,363
1,186
987
759
634
549
22,714
24,260
22,859
22,625
23,026
22,756
2,747
2,640
2,541
2,469
2,587
2,501
2,406
0
17,658
17,658
17,658
10,661
8
13
18
21
135
218
340
239
232
217
197
177
157
224
262
245
191
782
1,026
1,209
1,558
7,766
8,155
8,553
9,222
9,327
10,214
48,941
49,640
64,194
64,263
62,500
63,160
59,851
60,237
60,235
61,769
56,746
59,034
60,763
62,947
62,94760,76359,03456,74661,76960,23560,23759,85163,16062,50064,26364,19449,64048,94110,2149,3279,2228,5538,1557,7661,5581,2091,026782191245262224157177197217232239340218135211813810,66117,65817,65817,65802,4062,5012,5872,4692,5412,6402,74722,75623,02622,62522,85924,26022,7145496347599871,1861,3631,4571,6251,6811,8511,7461,7161,9161,4331,3851,4031,8611,0441,02694675,39176,13800000
       Warrants
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
17,658
17,658
17,658
10,659
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000000000000000000000010,65917,65817,65817,65800000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
1,007
584
458
542
1,183
883
602
472
178
186
202
207
247
257
199
204
225
22,486
24,106
22,761
22,560
22,975
22,715
2,715
2,617
2,528
2,467
2,587
2,501
2,406
0
0
0
0
2
8
13
18
21
135
218
340
239
232
217
197
177
157
224
262
245
191
782
1,026
1,209
1,558
1,012
1,413
2,174
2,861
3,237
4,545
3,598
5,180
3,613
5,129
4,823
7,034
4,373
5,544
6,466
9,074
5,305
0
12,660
0
012,66005,3059,0746,4665,5444,3737,0344,8235,1293,6135,1803,5984,5453,2372,8612,1741,4131,0121,5581,2091,0267821912452622241571771972172322393402181352118138200002,4062,5012,5872,4672,5282,6172,71522,71522,97522,56022,76124,10622,4862252041992572472072021861784726028831,1835424585841,0070000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,481
2,441
2,587
2,501
2,406
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000000000000000000000000000000002,4062,5012,5872,4412,48100000000000000000000000000000000000
> Total Stockholder Equity
25,871
6,412
0
0
0
-52,671
-58,415
42,792
37,359
30,680
32,371
61,150
49,197
39,371
39,859
88,546
78,401
67,159
56,795
144,270
129,734
113,934
98,667
81,204
66,242
52,992
38,386
26,413
18,967
12,114
7,098
3,156
-174
29,688
38,108
32,821
28,144
23,362
17,585
12,708
17,664
84,984
79,662
181,475
180,754
182,131
365,460
350,108
330,489
309,489
285,094
255,821
227,346
199,762
445,251
408,815
578,058
518,411
457,524
415,140
377,326
335,285
304,169
264,720
223,440
479,079
418,356
388,914
689,289
699,135
638,382
663,013
654,867
627,009
581,606
564,838
566,955
540,894
444,797
434,848
425,686
400,413
374,258
395,793
362,174
431,755
431,755362,174395,793374,258400,413425,686434,848444,797540,894566,955564,838581,606627,009654,867663,013638,382699,135689,289388,914418,356479,079223,440264,720304,169335,285377,326415,140457,524518,411578,058408,815445,251199,762227,346255,821285,094309,489330,489350,108365,460182,131180,754181,47579,66284,98417,66412,70817,58523,36228,14432,82138,10829,688-1743,1567,09812,11418,96726,41338,38652,99266,24281,20498,667113,934129,734144,27056,79567,15978,40188,54639,85939,37149,19761,15032,37130,68037,35942,792-58,415-52,6710006,41225,871
   Common Stock
0
0
0
0
0
0
0
2
2
2
2
2
2
2
2
3
3
3
3
4
4
4
4
4
4
4
4
4
4
4
4
4
4
4
5
5
5
5
5
5
6
7
7
8
9
9
10
10
10
10
10
10
10
10
11
11
12
12
12
12
12
12
12
12
12
14
14
14
15
15
15
15
16
16
16
16
16
16
16
16
16
16
16
16
16
16
161616161616161616161616161615151515141414121212121212121212111110101010101010109987765555554444444444444443333222222220000000
   Retained Earnings Total Equity000-2,412,5720-2,327,826-2,300,643-2,266,632-2,153,576-2,110,482-2,096,025-2,052,154-1,985,706-1,918,946-1,834,286-1,792,145-1,704,122-1,651,086-1,609,108-1,554,167-1,468,863-1,403,371-1,341,233-1,277,967-1,223,671-1,154,801-1,089,553-1,022,112-933,979-855,283-783,670-712,348-662,586-616,802-577,896-538,518-498,143-469,777-444,991-423,496-405,668-393,619-382,924-373,843-367,720-360,910-358,508-353,089-346,871-341,571-336,49500000000000000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
0
0
0
-2,499
-3,660
-3,102
-2,467
-1,793
-1,445
-1,188
-936
-639
-168
42
194
176
187
297
433
493
668
307
148
273
92
100
197
483
469
401
528
512
537
10
6
9
6
3
4
4
15
-26
84
48
0
94
77
-9
4
11
45
11
316
206
533
106
94
-97
-73
-399
-699
-500
-314
-372
207
554
420
297
1,525
1,480
509
36
34
38
-1
-192
-612
-843
-1,365
-975
-220
-535
-319
24
24-319-535-220-975-1,365-843-612-192-13834365091,4801,525297420554207-372-314-500-699-399-73-97941065332063161145114-9779404884-2615443696105375125284014694831971009227314830766849343329718717619442-168-639-936-1,188-1,445-1,793-2,467-3,102-3,660-2,49900000
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
369,301
369,704
370,219
370,663
371,208
378,564
452,693
453,483
564,417
574,280
587,742
788,946
794,995
800,179
807,631
823,598
833,696
844,093
862,327
1,157,272
1,192,268
1,432,796
1,452,272
1,479,530
1,504,778
1,532,188
1,559,343
1,582,823
1,606,441
1,627,113
1,948,300
1,972,302
1,997,454
2,339,940
2,402,945
2,428,987
2,495,804
2,573,288
2,612,663
2,633,710
2,660,809
2,677,422
2,694,646
2,712,025
2,736,318
2,754,861
0
2,787,034
0
0
0
0002,787,03402,754,8612,736,3182,712,0252,694,6462,677,4222,660,8092,633,7102,612,6632,573,2882,495,8042,428,9872,402,9452,339,9401,997,4541,972,3021,948,3001,627,1131,606,4411,582,8231,559,3431,532,1881,504,7781,479,5301,452,2721,432,7961,192,2681,157,272862,327844,093833,696823,598807,631800,179794,995788,946587,742574,280564,417453,483452,693378,564371,208370,663370,219369,704369,30100000000000000000000000000000000000
   Treasury Stock00000000000000000000000000000000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
18,194
20,091
126,626
126,773
126,755
133,686
168,244
168,345
168,426
177,910
238,254
239,220
240,446
242,625
340,742
342,115
343,293
344,231
345,416
346,227
346,815
347,391
348,137
349,322
350,872
351,357
351,771
352,541
353,278
367,505
369,301
369,704
370,219
370,663
371,208
378,564
452,693
453,483
564,417
574,280
587,742
788,946
794,995
800,179
807,631
823,598
833,696
844,093
862,327
1,157,272
1,192,268
1,432,796
1,452,272
1,479,530
1,504,778
1,532,188
1,559,343
1,582,823
1,606,441
1,627,113
1,948,300
1,972,302
1,997,454
2,339,940
2,402,945
2,428,987
2,495,804
2,573,288
2,612,663
2,633,710
2,660,809
2,677,422
2,694,646
2,712,025
2,736,318
2,754,861
2,770,923
2,787,034
2,807,770
2,839,111
2,862,552
2,862,5522,839,1112,807,7702,787,0342,770,9232,754,8612,736,3182,712,0252,694,6462,677,4222,660,8092,633,7102,612,6632,573,2882,495,8042,428,9872,402,9452,339,9401,997,4541,972,3021,948,3001,627,1131,606,4411,582,8231,559,3431,532,1881,504,7781,479,5301,452,2721,432,7961,192,2681,157,272862,327844,093833,696823,598807,631800,179794,995788,946587,742574,280564,417453,483452,693378,564371,208370,663370,219369,704369,301367,505353,278352,541351,771351,357350,872349,322348,137347,391346,815346,227345,416344,231343,293342,115340,742242,625240,446239,220238,254177,910168,426168,345168,244133,686126,755126,773126,62620,09118,19400000



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue726,437
Cost of Revenue-45,731
Gross Profit680,706680,706
 
Operating Income (+$)
Gross Profit680,706
Operating Expense-754,085
Operating Income-73,379-73,379
 
Operating Expense (+$)
Research Development351,619
Selling General Administrative406,559
Selling And Marketing Expenses0
Operating Expense754,085758,178
 
Net Interest Income (+$)
Interest Income17,234
Interest Expense-0
Other Finance Cost-0
Net Interest Income17,234
 
Pretax Income (+$)
Operating Income-73,379
Net Interest Income17,234
Other Non-Operating Income Expenses0
Income Before Tax (EBT)-51,036-95,722
EBIT - interestExpense = -73,379
-51,036
-61,286
Interest Expense0
Earnings Before Interest and Taxes (EBIT)-73,379-51,036
Earnings Before Interest and Taxes (EBITDA)-67,827
 
After tax Income (+$)
Income Before Tax-51,036
Tax Provision-10,250
Net Income From Continuing Ops-61,286-61,286
Net Income-61,286
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses799,816
Total Other Income/Expenses Net22,343-17,234
 

Technical Analysis of Acadia
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Acadia. The general trend of Acadia is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Acadia's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of ACADIA Pharmaceuticals Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 17.56 < 17.71 < 18.63.

The bearish price targets are: 16.78 > 16.59 > 16.13.

Tweet this
ACADIA Pharmaceuticals Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of ACADIA Pharmaceuticals Inc. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

ACADIA Pharmaceuticals Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of ACADIA Pharmaceuticals Inc. The current macd is -1.10323029.

The long score for the Moving Average Convergence/Divergence (MACD) is 3/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 2/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Acadia price going up in the near term. +2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Acadia. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Acadia price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
ACADIA Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) ChartACADIA Pharmaceuticals Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of ACADIA Pharmaceuticals Inc. The current adx is 48.45.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -4/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Acadia shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX > 25 && ADX trending up: The ADX is above 25 and indicates a strong bearish trend. The ADX is trending up, so the bearish trend is strengthening.
ACADIA Pharmaceuticals Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of ACADIA Pharmaceuticals Inc. The current sar is 17.99.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
ACADIA Pharmaceuticals Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of ACADIA Pharmaceuticals Inc. The current rsi is 29.91. The current phase is Oversold in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is 0/(-13 +13).

  • Oversold in bear market: Short-term excessive selling, potential for relief rally. Be cautious, consider taking short-term long positions. +1
  • Trending down: The RSI is trending down. -1
ACADIA Pharmaceuticals Inc Daily Relative Strength Index (RSI) ChartACADIA Pharmaceuticals Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of ACADIA Pharmaceuticals Inc. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Acadia price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
ACADIA Pharmaceuticals Inc Daily Stochastic Oscillator ChartACADIA Pharmaceuticals Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of ACADIA Pharmaceuticals Inc. The current cci is -110.75145313.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
ACADIA Pharmaceuticals Inc Daily Commodity Channel Index (CCI) ChartACADIA Pharmaceuticals Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of ACADIA Pharmaceuticals Inc. The current cmo is -38.98207378.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
ACADIA Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) ChartACADIA Pharmaceuticals Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of ACADIA Pharmaceuticals Inc. The current willr is -76.84729064.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Acadia is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
ACADIA Pharmaceuticals Inc Daily Williams %R ChartACADIA Pharmaceuticals Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of ACADIA Pharmaceuticals Inc. The current atr is 0.64857502.

ACADIA Pharmaceuticals Inc Daily Average True Range (ATR) ChartACADIA Pharmaceuticals Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of ACADIA Pharmaceuticals Inc. The current obv is -42,953,364.

ACADIA Pharmaceuticals Inc Daily On-Balance Volume (OBV) ChartACADIA Pharmaceuticals Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of ACADIA Pharmaceuticals Inc. The current mfi is 26.70.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
ACADIA Pharmaceuticals Inc Daily Money Flow Index (MFI) ChartACADIA Pharmaceuticals Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for ACADIA Pharmaceuticals Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-04DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-05DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-06MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-07STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-12STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-13MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-20STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-02RSI SHORT ENTRY LONG CLOSE70 crossover to downside
2024-01-03ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-01-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-01-10CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-11SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-19MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-29STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-30STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-02STOCH LONG EXITThe %K line crosses below the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-05STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-09DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-12CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-22STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-27DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-06WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-07STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-20STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-25STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-01MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-04-02WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-04SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-04-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-08WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-11BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-12STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-15STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
2024-04-18STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

ACADIA Pharmaceuticals Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of ACADIA Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5029.910
Ma 20Greater thanMa 5017.800
Ma 50Greater thanMa 10021.174
Ma 100Greater thanMa 20024.037
OpenGreater thanClose17.260
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Acadia with someone you think should read this too:
  • Are you bullish or bearish on Acadia? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Acadia? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about ACADIA Pharmaceuticals Inc

I send you an email if I find something interesting about ACADIA Pharmaceuticals Inc.


Comments

How you think about this?

Leave a comment

Stay informed about ACADIA Pharmaceuticals Inc.

Receive notifications about ACADIA Pharmaceuticals Inc in your mailbox!